MEPs water down price transparency proposal as clash with ministers looms
This article was originally published in Scrip
Executive Summary
An influential European Parliament committee has rejected proposals by the European Commission to reduce maximum pricing and reimbursement times for new medicines, and has also watered down plans to enforce those times more strictly. The committee did, however, come out in favour of shorter decision-making periods for generic drugs, and called for greater transparency on conflicts of interest within decision-making bodies.